At a glance
- Originator LEO Pharma
- Class Antineoplastics; Vitamins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 25 Jul 2001 Discontinued-II for Psoriasis in Denmark (Topical)
- 20 Oct 1999 A preclinical study has been added to the Musculoskeletal disorders pharmacodynamics section
- 29 Jan 1997 New profile